Skip to main content
Top
Published in: Current Hematologic Malignancy Reports 6/2018

01-12-2018 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

Authors: Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Michael A. Thompson, Andrew A. Lane

Published in: Current Hematologic Malignancy Reports | Issue 6/2018

Login to get access

Abstract

Purpose of Review

Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.

Recent Findings

Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient caregiver and support groups. One example of a rare cancer that has seen an increase in available information via Twitter is blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This field has recently experienced a new wave of interest from various healthcare stakeholders in light of key new scientific breakthroughs and novel clinical trials now starting to be available.

Summary

In order to bring all relevant healthcare stakeholders together, the investigators of this article created a disease-specific Twitter community: #BPDCN = “blastic plasmacytoid dendritic cell neoplasm on social media” which has led to higher levels of engagement and discussion in the field. This article focuses on our analysis of advanced Twitter user-metrics in the second year of #BPDCN and discusses future directions for this rare cancer online disease community.
Literature
1.
go back to reference Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef
2.
go back to reference Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–46.CrossRef Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–46.CrossRef
3.
go back to reference Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21–3.CrossRef Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21–3.CrossRef
4.
go back to reference Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–61.CrossRef Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–61.CrossRef
5.
go back to reference Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRef Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRef
6.
go back to reference Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283–6.CrossRef Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283–6.CrossRef
7.
go back to reference Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471–85.CrossRef Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471–85.CrossRef
8.
go back to reference Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRef Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRef
9.
go back to reference Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRef Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRef
10.
go back to reference Pemmaraju N, Kantarjian, H. M., Khoury, J. D., O'Brien, S. M., Cortes, J. E., Garcia-Manero, G., Jabbour, E. J., Jain, N., Alvarado, Y., Duvic, M., Aung, P., Qazilbash, M. H., Yin, C. C., Konoplev, S. N., Patel, K. P., Pierce, S., Brandt, M., & Konopleva, M. Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 2017;130(Suppl 1). Pemmaraju N, Kantarjian, H. M., Khoury, J. D., O'Brien, S. M., Cortes, J. E., Garcia-Manero, G., Jabbour, E. J., Jain, N., Alvarado, Y., Duvic, M., Aung, P., Qazilbash, M. H., Yin, C. C., Konoplev, S. N., Patel, K. P., Pierce, S., Brandt, M., & Konopleva, M. Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 2017;130(Suppl 1).
11.
go back to reference Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRef Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRef
12.
go back to reference • Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2 This paper is a mini-review which can serve as a quick primer to introduce the medical /clinical topic of blastic plasmacytoid dendritic cell neoplasm.PubMed • Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2 This paper is a mini-review which can serve as a quick primer to introduce the medical /clinical topic of blastic plasmacytoid dendritic cell neoplasm.PubMed
13.
go back to reference Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic Plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax. Cancer discovery. 2017;7:156–64.CrossRef Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic Plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax. Cancer discovery. 2017;7:156–64.CrossRef
14.
go back to reference Pemmaraju N. Novel pathways and potential therapeutic strategies for Blastic Plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. Curr Hematol Malig Rep. 2017;12:510–2.CrossRef Pemmaraju N. Novel pathways and potential therapeutic strategies for Blastic Plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. Curr Hematol Malig Rep. 2017;12:510–2.CrossRef
15.
go back to reference Pemmaraju N ea. RESULTS OF PIVOTAL PHASE 2 TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM. EHA 2018, Abstract #S116 2018. Pemmaraju N ea. RESULTS OF PIVOTAL PHASE 2 TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM. EHA 2018, Abstract #S116 2018.
16.
go back to reference Pemmaraju N, Gupta V, Thompson MA, Lane AA. Social media and internet resources for patients with Blastic Plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep. 2016;11:462–7.CrossRef Pemmaraju N, Gupta V, Thompson MA, Lane AA. Social media and internet resources for patients with Blastic Plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep. 2016;11:462–7.CrossRef
17.
go back to reference •• Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. Curr Hematol Malig Rep. 2015;10:405–12 This paper is a very practical, highly relevant primer on the basics of social media for professional use, aimed at the healthcare provider in a busy practice with limited time.CrossRef •• Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. Curr Hematol Malig Rep. 2015;10:405–12 This paper is a very practical, highly relevant primer on the basics of social media for professional use, aimed at the healthcare provider in a busy practice with limited time.CrossRef
18.
go back to reference Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782 4–5, 91. Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782 4–5, 91.
19.
go back to reference Thompson MA. Using social media to learn and communicate: it is not about the tweet. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2015;35:206–11.CrossRef Thompson MA. Using social media to learn and communicate: it is not about the tweet. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2015;35:206–11.CrossRef
21.
go back to reference Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Analysis of first-year twitter metrics of a rare disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on social media: #BPDCN. Curr Hematol Malig Rep. 2017;12:592–7.CrossRef Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Analysis of first-year twitter metrics of a rare disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on social media: #BPDCN. Curr Hematol Malig Rep. 2017;12:592–7.CrossRef
22.
go back to reference Katz MS, Utengen A, Anderson PF, Thompson, MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol 2015;33; suppl abstr 6520. Katz MS, Utengen A, Anderson PF, Thompson, MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol 2015;33; suppl abstr 6520.
23.
go back to reference Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRef Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRef
24.
go back to reference Patel SS, Majhail NS. Twitter use in the hematopoietic cell transplantation community. Curr Hematol Malig Rep. 2018;13:53–8.CrossRef Patel SS, Majhail NS. Twitter use in the hematopoietic cell transplantation community. Curr Hematol Malig Rep. 2018;13:53–8.CrossRef
25.
go back to reference Gerds AT, Chan T. Social Media in Hematology in 2017: dystopia, utopia, or somewhere in-between? Curr Hematol Malig Rep. 2017;12:582–91.CrossRef Gerds AT, Chan T. Social Media in Hematology in 2017: dystopia, utopia, or somewhere in-between? Curr Hematol Malig Rep. 2017;12:582–91.CrossRef
26.
go back to reference •• Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. Journal of oncology practice / American Society of Clinical Oncology. 2017;13:e623–e31 This original analyis describes the rise of Twitter use at one of the major medical meetings in all of medicine, the ASCO annual meeting and analyzes user metrics during these meetings over time.CrossRef •• Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. Journal of oncology practice / American Society of Clinical Oncology. 2017;13:e623–e31 This original analyis describes the rise of Twitter use at one of the major medical meetings in all of medicine, the ASCO annual meeting and analyzes user metrics during these meetings over time.CrossRef
27.
go back to reference Logan AC. Using social Media at National Meetings in hematology-optimal use, tips, strategies, and limitations. Curr Hematol Malig Rep. 2017;12:605–10.CrossRef Logan AC. Using social Media at National Meetings in hematology-optimal use, tips, strategies, and limitations. Curr Hematol Malig Rep. 2017;12:605–10.CrossRef
28.
go back to reference Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRef Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRef
Metadata
Title
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community
Authors
Naveen Pemmaraju
Audun Utengen
Vikas Gupta
Michael A. Thompson
Andrew A. Lane
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-018-0490-6

Other articles of this Issue 6/2018

Current Hematologic Malignancy Reports 6/2018 Go to the issue

Myelodysplastic Syndromes (M Savona, Section Editor)

Leveraging Hypomethylating Agents for Better MDS Therapy

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Online and Social Media Resources for Patients with MDS